Dopamine D3 receptor gene variation: Impact on electroconvulsive therapy response and ventral striatum responsiveness in depression

International Journal of Neuropsychopharmacology

Volumn 16, Issue 7, 2013, Pages 1443-1459

  Dannlowski, Udo ^a   Domschke, Katharina ^a   Birosova, Eva ^b   Lawford, Bruce ^c,d   Young, Ross ^d   Voisey, Joanne ^d   Morris, C Phillip ^d   Suslow, Thomas ^e   Konrad, Carsten ^f   Kugel, Harald ^a   Ohrmann, Patricia ^a   Bauer, Jochen ^a   Schöning, Sonja ^a   Zavorotnyy, Maxim ^a   Diemer, Julia ^a   Arolt, Volker ^a   Baune, Bernhard T ^g   Zwanzger, Peter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Depression; DRD3; electroconvulsive therapy; pharmacogenetics; ventral striatum

Indexed keywords

DOPAMINE 3 RECEPTOR;

ADULT; ARTICLE; CAUCASIAN; CORPUS STRIATUM; ELECTROCONVULSIVE THERAPY; FACIAL EXPRESSION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; BASAL GANGLIA; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FACE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXYGEN; PATTERN RECOGNITION, VISUAL; PHOTIC STIMULATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3;

EID: 84880563249     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001659     Document Type: Article

References (98)

1. Aarts E, Roelofs A, Franke B, Rijpkema M, et al. (2010). Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 35, 1943-1951.
2. Abrams R (2002). Stimulus titration and ECT dosing. Journal of ECT 18, 3-9.
3. Akaike H (1974). A new look at the statistical model identification. IEEE Transactions on Automatic Control 19, 716-723.
4. Anttila S, Huuhka K, Huuhka M, Illi A, et al. (2008). Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics Journal 8, 113-116.
5. Baghai TC, Marcuse A, Brosch M, Schu? leC, et al. (2006). The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry 7, 82-90.
6. Barr AM, Zis AP, Phillips AG (2002). Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats. Psychopharmacology 159, 196-202.
7. Baune BT, DannlowskiU, Domschke K, Janssen DGA, et al. (2010). The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biological Psychiatry 67, 543-549.
8. Benedetti F, Serretti A, Colombo C, Lilli R, et al. (2003). Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatry Research 118, 241-247.
9. Beninger RJ, Banasikowski TJ (2008). Dopaminergic mechanism of reward-related incentive learning : focus on the dopamine D(3) receptor. Neurotoxicity Research 14, 57-70.
10. Benjamini Y, Hochberg Y (1995). Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57, 289-300.
11. Bewernick BH, Hurlemann R, Matusch A, Kayser S, et al. (2010). Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biological Psychiatry 67, 110-116.
12. Birkenha?ger TK, Pluijms EM, Ju MR, Mulder PG, et al. (2010). Influence of age on the efficacy of electroconvulsive therapy in major depression: A retrospective study. Journal of Affective Disorders 126, 257-261.
13. Camara E, Kra?mer UM, Cunillera T, Marco-Pallare's J, et al. (2010). The effects of COMT (Val108/158Met) and DRD4 (SNP-521) dopamine genotypes on brain activations related to valence and magnitude of rewards. Cerebral Cortex 20, 1985-1996.
14. Carter KW,McCaskie PA, Palmer LJ (2008). SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinformatics 25, 557.
15. Cassidy F, Weiner RD, Cooper TB, Carroll BJ (2010). Combined catecholamine and indoleamine depletion following response to ECT. British Journal of Psychiatry 196, 493-494.
16. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S (2006). Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. European Journal of Neuroscience 23, 1944-1948.
17. Chernoloz O, El Mansari M, Blier P (2009). Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychpharmacology 34, 651-661.
18. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, et al. (2000). Comparison of paramipexole, fluoxetine and placebo in patients with major depression. Depression and Anxiety 11, 58-65.
19. Damm J, Eser D, Schu? le C, Obermeier M, et al. (2010). Influence of age on effectiveness and tolerability of electroconvulsive therapy. Journal of ECT 26, 282-288.
20. DannlowskiU, Kersting A, Donges U, Lalee-Mentzel J, et al. (2006). Subliminal facial affect priming is associated with therapy response in clinical depression. European Archives of Psychiatry and Clinical Neuroscience 256, 215-221.
21. Dannlowski U, Konrad C, Kugel H, Zwitserlood P, et al. (2010). Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. NeuroImage 53, 893-898.
22. Dannlowski U, Ohrmann P, Bauer J, Deckert J, et al. (2008). 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 33, 418-424.
23. Dannlowski U, Ohrmann P, Bauer J, Kugel H, et al. (2007). Amygdala reactivity to masked negative faces is associated with automatic judgmental bias in major depression: A 3T fMRI study. Journal of Psychiatry and Neuroscience 32, 423-429.
24. Davidovich O, Kimmel G, Shamir R (2007). GEVALT: an integrated software tool for genotype analysis. BMC Bioinformatics 8, 36.
25. Dikeos DG, Papadimitriou GN, Avramopoulos D, Karadima G, et al. (1999). Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder. Psychiatric Genetics 9, 189-195.
26. Domschke K, Dannlowski U, Hohoff C, Ohrmann P, et al. (2010). Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. European Neuropsychopharmacology 20, 301-309.
27. Domschke K, Dannlowski U, Ohrmann P, Lawford B, et al. (2008). Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. European Neuropsychopharmacology 18, 751-759.
28. Domschke K, Nitsche S, Diemer J, Zavorotnyy M, et al. (2009). COMT val158met influence on electroconvulsive therapy response in major depression. American Journal of Medical Genetics (Neuropsychiatric Genetics) 153, 286-290.
29. Dreher JC, Kohn P, Kolachana B, Weinberger DR, et al. (2009). Variation in dopamine genes influences responsivity of the human reward system. Proceedings of the National Academy of Sciences USA 106, 617-622.
30. Ekman P, Friesen WV (1976). Pictures of Facial Affect. Palo Alto, CA, USA: Consulting Psychologists Press.
31. Epstein J, Pan H, Kocsis JH, Yang Y, et al. (2006). Lack of ventral striatal response to positive stimuli in depressed vs. normal subjects. American Journal of Psychiatry 163, 1784-1790.
32. Fernandes B, Gama CS, Massuda R, Torres M, et al. (2009). Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neuroscience Letters 453, 195-198.
33. Feske U, Mulsant BH, Pilkonis PA, Soloff P, et al. (2004). Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. American Journal of Psychiatry 161, 2073-2080.
34. Forbes EE, Brown SM, Kimak M, Ferrell RE, et al. (2009a). Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Molecular Psychiatry 14, 60-70.
35. Forbes EE, Christopher May J, Siegle GJ, Ladouceur CD, et al. (2006). Reward-related decision-making in pediatric major depressive disorder : an fMRI study. Journal of Child Psychology and Psychiatry 47, 1031-1040.
36. Forbes EE, Hariri AR, Martin SL, Silk JS, et al. (2009b). Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. American Journal of Psychiatry 166, 64-73.
37. Forbes EE, Olino TM, Ryan ND, Birmaher B, et al. (2010). Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorder. Cognitive and Affective Behavioral Neuroscience 10, 107-118.
38. Forman SD, Cohen JD, Fitzgerald M, Eddy WF, et al. (1995). Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magnetic Resonance in Medicine 33, 636-647.
39. Gur RC, Erwin RJ, Gur RE, Zwil AS, et al. (1992). Facial emotion discrimination, II : behavioral findings in depression. Psychiatry Research 42, 241-251.
40. Hahn T, Heinzel S, Dresler T, Plichta MM, et al. (2011). Association between reward-related activation in the ventral striatum and trait reward sensitivity is moderated by dopamine transporter genotype. Human Brain Mapping 32, 1557-1565.
41. Halperin E, Kimmel G, Shamir R (2005). Tag SNP selection in genotype data for maximizing SNP prediction accuracy. Bioinformatics 21, 195-203.
42. Henderson AS, Korten AE, Jorm AF, Jacomb PA, et al. (2000). COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders. American Journal of Medical Genetics 96, 102-107.
43. Huuhka K, Anttila S, Huuhka M, Hietala J, et al. (2008). Dopamine 2 receptor C957T and catechol-omethyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neuroscience Letters 448, 79-83.
44. Huuhka K, Anttila S, Huuhka M, Leinonen E, et al. (2007). Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience 257, 31-35.
45. International HapMap Consortium (2003). The International HapMap Project. Nature 426, 789-796.
46. Jha A, Stein G (1996). Decreased efficacy of combined benzodiazepines and unilateral ECT in treatment of depression. Acta Psychiatrica Scandinavica 94, 101-104.
47. Jo?nsson E, Sedvall G, Brené S, Gustavsson JP, et al. (1996). Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biological Psychiatry 40, 1032-1043.
48. Keedwell PA, Andrew C, Williams SCR, Brammer MJ, et al. (2005). The neural correlates of anhedonia in major depressive disorder. Biological Psychiatry 58, 843-853.
49. Kirsch P, Reuter M, Mier D, Lonsdorf T, et al. (2006). Imaging gene-substance interactions : The effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neuroscience Letters 405, 196-201.
50. Krugel LK, Biele G, Mohr PNC, Li SC, et al. (2009). Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions. Proceedings of the National Academy of Sciences USA 106, 17951-17956.
51. Lammers CH, Diaz J, Schwartz JC, Sokoloff P (2000). Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Molecular Psychiatry 5, 378-388.
52. Landau AM, Chakravarty MM, Clark CM, Zis AP, et al. (2011). Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 36, 511-518.
53. Lattanzi L, Dell'Osso L, Cassano P, Pini S, et al. (2002). Pramipexole in treatment-resistant depression: A 16-week naturalistic study. Bipolar Disorders 4, 307-314.
54. Lawrence NS, Williams AM, Surguladze S, Giampietro V, et al. (2004). Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biological Psychiatry 55, 578-587.
55. Lehrl S (1995). Mehrfachwahl-Wortschatz-Intelligenztest MWTB. Go?ttingen, Germany: Hogrefe.
56. Leppa?nen JM, Milders M, Bell JS, Terriere E, et al. (2004). Depression biases the recognition of emotionally neutral faces. Psychiatry Research 128, 123-133.
57. Maj J, Dziedziek-Waslylewska M, Rogo'z R, Rogo'z T (1998). Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. European Journal of Pharmacology 351, 31-37.
58. Maj J, Rogo'z Z (1999). Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on alpha-1 adrenergic, dopamine, and serotonin systems. Journal of Neural Transmission 106, 197-211.
59. Maj J, Rogoz A, Skuza G, Kofodziejczyk K (1997). Antidepressant effects of pramipexole, a novel dopamine receptor agonist. Journal of Neural Transmission 104, 525-533.
60. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003). An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19, 1233-1239.
61. Manki H, Kanba S, Muramatsu T, Higuchi S, et al. (1996). Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. Journal of Affective Disorders 40, 7-13.
62. Mann JJ (1998). Neurobiological correlates of the antidepressant action of electroconvulsive therapy. Journal of ECT 14, 172-180.
63. Merkl A, Heuser I, Bajbouj M (2009). Antidepressant electroconvulsive therapy: mechanism of action, recent advances and limitations. Experimental Neurology 219, 20-26.
64. Nestler EJ, Carlezon WA (2006). The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 59, 1151-1159.
65. Nothdurfter C, Eser D, Schu? le C, Zwanzger P, et al. (2006). The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry 7, 162-170.
66. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, et al. (2006). Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry 67, 46-49.
67. O'Connor MK, Knapp R, Husain M, Rummans TA, et al. (2001). The influence of age on the response of major depression to electroconvulsive therapy: A CORE Report. American Journal of Geriatric Psychiatry 9, 382-390.
68. O'Doherty J, Dayan P, Schultz J, Deichmann R, et al. (2004). Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science 304, 452-454.
69. Oeth P, Beaulieu M, Park C, Kosman D, et al. (2007). iPLEXTM assay: increased plexing efficiency and flexibility for MassARRAY System through single base primer extension with mass-modified terminators (http://www.agrf.org.au/ docstore/snp/iPlex.pdf) Accessed 11 April 2011.
70. Perlis RH, Adams DH, Fijal B, Sutton VK, et al. (2010). Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. Journal of Clinical Psychiatry 71, 599-605.
71. Persad SM, Polivy J (1993). Differences between depressed and nondepressed individuals in the recognition of and response to facial emotional cues. Journal of Abnormal Psychology 102, 358-368.
72. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, et al. (2009a). Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. American Journal of Psychiatry 166, 702-710.
73. Pizzagalli DA, Wacker J, Dillon DG (2009b). The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia : integration of resting EEG, fMRI, and volumetric techniques. NeuroImage 46, 327-337.
74. Porcelli S, Drago A, Fabbri C, Serretti A (2011). Mechanisms of antidepressant action : an integrated dopaminergic perspective. Progress in Neuropsychopharmacology and Biological Psychiatry 35, 1532-1543.
75. Reker M, Ohrmann P, Rauch AV, Kugel H, et al. (2010). Individual differences in alexithymia and brain response to masked emotion faces. Cortex 46, 658-667.
76. Rogo'z R, Dziedzieka-Wasylewska M (1999). Effects of antidepressant drugs on the dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding: an autoradiographic analysis. Naunyn Schmiedebergs Archives of Pharmacology 359, 178-186.
77. Sackeim HA (2001). The definition and meaning of treatment-resistant depression. Journal of Clinical Psychiatry 62, 10-17.
78. Schlaepfer TE, Cohen MX, Frick C, Kosel M, et al. (2008). Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33, 368-377.
79. Schmack K, Schlagenhauf F, Sterzer P, Wrase J, et al. (2008). Catechol-O-methyltransferase val158met genotype influences neural processing of reward anticipation. NeuroImage 42, 1631-1638.
80. Schumann G, Benedetti F, Voderholzer U, Kammerer N, et al. (2001). Antidepressive response to sleep deprivation in unipolar depression is not associated with dopamine D3 receptor genotype. Neuropsychobiology 43, 127-130.
81. Serretti A, Lattuada E, Cusin C, Lilli R, et al. (1999). Dopamine D3 receptor gene not associated with symptomatology of major psychoses. American Journal of Medical Genetics 88, 476-480.
82. Serretti A, Lilli R, Lorenzi C, Franchini L, et al. (1998). Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychoparmacology 1, 125-129.
83. Serretti A, Macciardi F, Cusin C, Lattuada E, et al. (2000). Linkage of mood disorders with D2, D3 and TH genes: A multicenter study. Journal of Affective Disorders 58, 51-61.
84. Shirayama Y, Chaki S (2006). Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Current Neuropharmacology 4, 277-291.
85. Stein DJ (2008). Depression, anhedonia, and psychomotor symptoms: The role of dopaminergic neurocircuitry. CNS Spectrum 13, 561-565.
86. Strome EM, Zis AP, Doudet DJ (2007). Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDAlesioned rats. Journal of Psychiatry and Neuroscience 32, 193-202.
87. Suslow T, DannlowskiU, Lalee-Mentzel J, Donges US, et al. (2004). Spatial processing of facial emotion in patients with unipolar depression: A longitudinal study. Journal of Affective Disorders 83, 59-63.
88. Suslow T, Konrad C, Kugel H, Rumstadt D, et al. (2010). Automatic mood-congruent amygdala responses to masked facial expressions in major depression. Biological Psychiatry 67, 155-160.
89. Suslow T, Kugel H, Rauch AV, Dannlowski U, et al. (2009). Attachment avoidance modulates neural response to masked facial emotion. Human Brain Mapping 30, 3553-3562.
90. Szegedi A, Wetzel J, Hillert A, Kleiser E, et al. (1996). Pramipexole, a novel selective dopamine antagonist in major depression. Movement Disorders 11, 266.
91. Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, et al. (2008). The association of genotypic combination of the DRD3 and BDNF polymorphisms on the adhesion interthalamica and medial temporal lobe structures. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 1236-1242.
92. Tew JD, Mulsant BH, Haskett RF, Prudic J, et al. (1999). Acute efficacy of ECT in the treatment of major depression in the old-old. American Journal of Psychiatry 156, 1865-1870.
93. Wahlund B, von Rosen D (2003). ECT of major depressed patients in relation to biological and clinical variables : A brief overview. Neuropsychopharmacology 28, 21-26.
94. Willner P (1997). The mesolimbic dopamine system as a target for rapid antidepressant action. International Clinical Psychopharmacology 12, 7-14.
95. Willner P, Lappas S, Cheeta S, Muscat R (1994). Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 115, 454-462.
96. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997). SKID-I, Strukturiertes Klinisches Interview fu? r DSM-IV. Go? ttingen, Germany: Hogrefe.
97. Yacubian J, Sommer T, Schroeder K, Gla?scher J, et al. (2007). Gene-gene interaction associated with neural reward sensitivity. Proceedings of the National Academy of Sciences USA 104, 8125-8130.
98. Zarate CA, Payne JL, Singh J, Quiroz JA, et al. (2004). Pramipexole for bipolar II depression: A placebocontrolled proof of concept study. Biological Psychiatry 56, 54-60.